Published in Am J Obstet Gynecol on November 01, 2004
The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer (2012) 10.90
Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One (2009) 2.36
Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology (2012) 1.78
An immunologic portrait of cancer. J Transl Med (2011) 1.50
Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer. PLoS One (2008) 1.14
Depressed and anxious mood and T-cell cytokine expressing populations in ovarian cancer patients. Brain Behav Immun (2008) 1.13
Chimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironment. J Immunol (2009) 1.07
Favorable prognostic value of SOCS2 and IGF-I in breast cancer. BMC Cancer (2007) 1.00
Multifaceted therapeutic targeting of ovarian peritoneal carcinomatosis through virus-induced immunomodulation. Mol Ther (2012) 0.99
Ex vivo expansion of human CD8+ T cells using autologous CD4+ T cell help. PLoS One (2012) 0.91
High STAT1 mRNA levels but not its tyrosine phosphorylation are associated with macrophage infiltration and bad prognosis in breast cancer. BMC Cancer (2014) 0.89
Tumor infiltration by Tbet+ effector T cells and CD20+ B cells is associated with survival in gastric cancer patients. Oncoimmunology (2015) 0.87
Tumor infiltrating lymphocytes in ovarian cancer. Cancer Biol Ther (2015) 0.85
Selective toxicity of rose bengal to ovarian cancer cells in vitro. Int J Physiol Pathophysiol Pharmacol (2012) 0.84
The tumor area occupied by Tbet+ cells in deeply invading cervical cancer predicts clinical outcome. J Transl Med (2015) 0.79
Prognostic biomarkers in ovarian cancer. Cancer Biomark (2011) 0.75
Interferon signaling in ascites-associated macrophages is linked to a favorable clinical outcome in a subgroup of ovarian carcinoma patients. BMC Genomics (2017) 0.75
Epigenetic stem cell signature in cancer. Nat Genet (2006) 9.62
The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res (2005) 4.02
FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res (2007) 3.79
Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res (2004) 3.23
hCDC4 gene mutations in endometrial cancer. Cancer Res (2002) 2.36
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst (2002) 2.25
Optimizing the outcome of microsurgical subinguinal varicocelectomy using isosulfan blue: a prospective randomized trial. J Urol (2006) 2.15
DNA methylation in serum of breast cancer patients: an independent prognostic marker. Cancer Res (2003) 2.14
Quantification of recent smoking behaviour using proton transfer reaction-mass spectrometry (PTR-MS). Wien Klin Wochenschr (2004) 2.03
Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer. Cancer Res (2006) 1.99
Methylation changes in faecal DNA: a marker for colorectal cancer screening? Lancet (2004) 1.80
Epigenotyping in peripheral blood cell DNA and breast cancer risk: a proof of principle study. PLoS One (2008) 1.75
DNA hypomethylation and ovarian cancer biology. Cancer Res (2004) 1.75
Prognostic significance of methylated RASSF1A and PITX2 genes in blood- and bone marrow plasma of breast cancer patients. Breast Cancer Res Treat (2011) 1.71
Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. Gynecol Oncol (2006) 1.69
Large-scale study of clinical impact of PSA velocity: long-term PSA kinetics as method of differentiating men with from those without prostate cancer. Urology (2007) 1.69
Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk. Prostate (2005) 1.68
Epigenetic variability in cells of normal cytology is associated with the risk of future morphological transformation. Genome Med (2012) 1.65
Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response. Eur J Immunol (2013) 1.63
DNA hypomethylation is prevalent even in low-grade breast cancers. Cancer Biol Ther (2004) 1.53
Comparison of the specificity of implantable dual chamber defibrillator detection algorithms. Pacing Clin Electrophysiol (2004) 1.46
Heterogeneous cross-talk of E2F family members is crucially involved in growth modulatory effects of interferon-gamma and EGF. Cancer Biol Ther (2006) 1.44
Clinical relevance of E2F family members in ovarian cancer--an evaluation in a training set of 77 patients. Clin Cancer Res (2007) 1.40
L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation. J Natl Cancer Inst (2013) 1.40
Prognostic significance of signal transducer and activator of transcription 1 activation in breast cancer. Clin Cancer Res (2002) 1.34
The dynamics and prognostic potential of DNA methylation changes at stem cell gene loci in women's cancer. PLoS Genet (2012) 1.33
Up-regulation of L1CAM is linked to loss of hormone receptors and E-cadherin in aggressive subtypes of endometrial carcinomas. J Pathol (2010) 1.20
Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol (2008) 1.19
Role of miR-34a as a suppressor of L1CAM in endometrial carcinoma. Oncotarget (2014) 1.18
High EGFR expression predicts poor prognosis in patients with squamous cell carcinoma of the oral cavity and oropharynx: a TMA-based immunohistochemical analysis. Oral Oncol (2006) 1.18
Quality assurance for detection of estrogen and progesterone receptors by immunohistochemistry in Austrian pathology laboratories. Virchows Arch (2002) 1.12
Role of DNA methylation and epigenetic silencing of HAND2 in endometrial cancer development. PLoS Med (2013) 1.10
Methylation status of the Ep-CAM promoter region in human breast cancer cell lines and breast cancer tissue. Cancer Lett (2006) 1.07
DNA methylation in serum and tumors of cervical cancer patients. Clin Cancer Res (2004) 1.06
Prognostic DNA methylation marker in serum of cancer patients. Ann N Y Acad Sci (2004) 1.06
Methylation status and expression of human telomerase reverse transcriptase in ovarian and cervical cancer. Gynecol Oncol (2004) 1.06
Expression of the E2F family of transcription factors and its clinical relevance in ovarian cancer. Ann N Y Acad Sci (2006) 1.06
Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo. Clin Cancer Res (2005) 1.05
Attenuation of cell adhesion in lymphocytes is regulated by CYTIP, a protein which mediates signal complex sequestration. EMBO J (2003) 1.04
The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer. Clin Cancer Res (2014) 1.04
Fatigue in ovarian carcinoma patients: a neglected issue? Cancer (2003) 1.02
Mammaglobin expression in gynecologic malignancies and malignant effusions detected by nested reverse transcriptase-polymerase chain reaction. Lab Invest (2002) 1.02
SFRP2 methylation in fecal DNA--a marker for colorectal polyps. Int J Colorectal Dis (2007) 1.02
High level HPV-16 E7 oncoprotein expression correlates with reduced pRb-levels in cervical biopsies. FASEB J (2004) 1.01
The Impact of Sample Storage Time on Estimates of Association in Biomarker Discovery Studies. J Clin Bioinforma (2011) 1.00
Favorable prognostic value of SOCS2 and IGF-I in breast cancer. BMC Cancer (2007) 1.00
Long non-coding RNAs as targets for cytosine methylation. RNA Biol (2013) 1.00
Atherosclerosis as a risk factor for benign prostatic hyperplasia. BJU Int (2006) 0.99
Extracellular matrix degradation and reduced nerve supply in refluxing ureteral endings. J Urol (2004) 0.99
Neoadjuvant gonadotropin-releasing hormone therapy before surgery may improve the fertility index in undescended testes: a prospective randomized trial. J Urol (2005) 0.98
Analysis of methylated genes in peritoneal fluids of ovarian cancer patients: a new prognostic tool. Clin Chem (2004) 0.98
Progesterone receptor repression of prolactin/signal transducer and activator of transcription 5-mediated transcription of the beta-casein gene in mammary epithelial cells. Mol Endocrinol (2006) 0.97
Analysis of aberrant DNA methylation and human papillomavirus DNA in cervicovaginal specimens to detect invasive cervical cancer and its precursors. Clin Cancer Res (2004) 0.96
Loss of interstitial cells of Cajal and gap junction protein connexin 43 at the vesicoureteral junction in children with vesicoureteral reflux. J Urol (2005) 0.95
CDH1 and CDH13 methylation in serum is an independent prognostic marker in cervical cancer patients. Int J Cancer (2004) 0.95
Impact of tonsillectomy on quality of life in adults with chronic tonsillitis. Swiss Med Wkly (2007) 0.94
Diverse functions of IGF/insulin signaling in malignant and noncancerous prostate cells: proliferation in cancer cells and differentiation in noncancerous cells. Endocrinology (2012) 0.94
Suppressor of cytokine signaling (SOCS)-1 is expressed in human prostate cancer and exerts growth-inhibitory function through down-regulation of cyclins and cyclin-dependent kinases. Am J Pathol (2009) 0.94
Intrarater reliability in the ultrasound diagnosis of medial and lateral orbital wall fractures with a curved array transducer. J Oral Maxillofac Surg (2006) 0.93
Pilot study: volatile organic compounds as a diagnostic marker for head and neck tumors. Head Neck (2008) 0.93
Selective response to insulin versus insulin-like growth factor-I and -II and up-regulation of insulin receptor splice variant B in the differentiated mouse mammary epithelium. Endocrinology (2009) 0.93
High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity. Mod Pathol (2012) 0.93
Shock wave therapy reduces necrotic flap zones and induces VEGF expression in animal epigastric skin flap model. J Reconstr Microsurg (2007) 0.93
The intravesical ureter in children with vesicoureteral reflux: a morphological and immunohistochemical characterization. J Urol (2003) 0.93
Detection of low molecular weight derivatives of cyclin E1 is a function of cyclin E1 protein levels in breast cancer. Cancer Res (2006) 0.92
Toll-like receptor 9 expression in breast and ovarian cancer is associated with poorly differentiated tumors. Cancer Sci (2010) 0.92
Interaction and functional interference of glucocorticoid receptor and SOCS1. J Biol Chem (2008) 0.92
DNA methylation changes in sera of women in early pregnancy are similar to those in advanced breast cancer patients. Clin Chem (2004) 0.91
E2F3a is critically involved in epidermal growth factor receptor-directed proliferation in ovarian cancer. Cancer Res (2010) 0.90
DNA ploidy, nuclear size, proliferation index and DNA-hypomethylation in ovarian cancer. Gynecol Oncol (2011) 0.90
HE4 is an independent prognostic marker in endometrial cancer patients. Gynecol Oncol (2012) 0.90
In situ proliferation contributes to accumulation of tumor-associated macrophages in spontaneous mammary tumors. Eur J Immunol (2014) 0.90
Suppressor of cytokine signaling-3 antagonizes cAMP effects on proliferation and apoptosis and is expressed in human prostate cancer. Am J Pathol (2006) 0.90
STAT1 activation in squamous cell cancer of the oral cavity: a potential predictive marker of response to adjuvant chemotherapy. Cancer (2007) 0.90
Tamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancer. PLoS One (2012) 0.89